PRESS RELEASE

Heidelberg Pharma Expands Management Team

- Dr. András Strassz promoted to Chief Medical Officer
- Dr. Mathias Locher joins to fill newly created position of Chief Development Officer

Ladenburg, Germany, 1 March 2021 – Heidelberg Pharma AG (FSE: HPHA) today announced the appointment of Dr. András Strassz as Chief Medical Officer and Dr. Mathias Locher as Chief Development Officer.

Dr. Strassz joined the company in April 2020 as Senior Medical Officer to build up the clinical development function. He has strong experience in clinical development, including in oncology. Dr. Strassz joined Heidelberg Pharma from Affimed, where he served as Medical Director. Previously, he held positions in clinical development at Sandoz and Amgen, among others. He holds both an MD and MBA from the University of Pécs, Hungary.

Dr. Locher has over 30 years of experience in drug development. He joins Heidelberg Pharma from Janssen (Pharmaceutical Companies of Johnson & Johnson), where he was Senior Director - External Innovation at the J&J London Innovation Centre. Prior to that, he held management positions at Covagen, Merck Serono, Micromet (now part of Amgen) and ASTA Medica. Dr. Locher holds a PhD in biochemistry from the University of Tuebingen.

Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG, commented: "I am very pleased that András Strassz and Mathias Locher are joining the Heidelberg Pharma management team. With our lead program, HDP-101, about to enter the clinic, we are evolving from a research organization to a clinical development company and with strengthening the team, we gain valuable know-how and necessary expertise. I look forward to working together with the growing team to achieve our goals."

About Heidelberg Pharma

Heidelberg Pharma is an oncology company and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.

Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets upamostat (formerly MESUPRON®) and TLX250-CDx (formerly REDECTANE®). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

Contact	**IR/PR support**
Heidelberg Pharma AG	MC Services AG
Corporate Communications	Katja Arnold (CIRO)
Sylvia Wimmer	Managing Director & Partner
Tel.: +49 89 41 31 38-29	Tel.: +49 89 210 228-40
Email: investors[at]hdpharma.com	Cell: +49 (0)160 9360 3022
Gregor-Mendel-Str. 22, 68526 Ladenburg	Email: katja.arnold[at]mc-services.eu